Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nissan Chemical Industries
NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a primary early stage indication of peripheral arterial disease (PAD). This trial is designed to assess the safety and efficacy of 4 mg and/or 8 mg NM-702 BID for 24 weeks to see if it improves peak walking time (PWT) more than placebo for the treatment of Intermittent Claudication.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stable, symptomatic, intermittent claudication due to occlusive atherosclerotic disease of the lower extremities
Median treadmill peak walking time between 90 and 600 seconds
